Resistance exercise as a treatment for sarcopenia: prescription and delivery
- PMID: 35150587
- PMCID: PMC8840798
- DOI: 10.1093/ageing/afac003
Resistance exercise as a treatment for sarcopenia: prescription and delivery
Abstract
Sarcopenia is a generalised skeletal muscle disorder characterised by reduced muscle strength and mass and associated with a range of negative health outcomes. Currently, resistance exercise (RE) is recommended as the first-line treatment for counteracting the deleterious consequences of sarcopenia in older adults. However, whilst there is considerable evidence demonstrating that RE is an effective intervention for improving muscle strength and function in healthy older adults, much less is known about its benefits in older people living with sarcopenia. Furthermore, evidence for its optimal prescription and delivery is very limited and any potential benefits of RE are unlikely to be realised in the absence of an appropriate exercise dose. We provide a summary of the underlying principles of effective RE prescription (specificity, overload and progression) and discuss the main variables (training frequency, exercise selection, exercise intensity, exercise volume and rest periods) that can be manipulated when designing RE programmes. Following this, we propose that an RE programme that consists of two exercise sessions per week and involves a combination of upper- and lower-body exercises performed with a relatively high degree of effort for 1-3 sets of 6-12 repetitions is appropriate as a treatment for sarcopenia. The principles of RE prescription outlined here and the proposed RE programme presented in this paper provide a useful resource for clinicians and exercise practitioners treating older adults with sarcopenia and will also be of value to researchers for standardising approaches to RE interventions in future sarcopenia studies.
Keywords: exercise prescription; muscle strength; older people; physical performance; resistance exercise; sarcopenia.
© The Author(s) 2022. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Figures
References
-
- Cruz-Jentoft AJ, Sayer AA. Sarcopenia. The Lancet 2019; 393: 2636–46. - PubMed
-
- Landi F, Liperoti R, Russo A et al. Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study. Clin Nutr 2012; 31: 652–8. - PubMed
-
- Landi F, Cruz-Jentoft AJ, Liperoti R et al. Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study. Age Ageing 2013; 42: 203–9. - PubMed
-
- Tanimoto Y, Watanabe M, Sun W et al. Association of sarcopenia with functional decline in community-dwelling elderly subjects in Japan: sarcopenia and functional decline. Geriatr Gerontol Int 2013; 13: 958–63. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical